- Trials with a EudraCT protocol (11)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
11 result(s) found for: Bioactivity.
Displaying page 1 of 1.
EudraCT Number: 2005-004475-37 | Sponsor Protocol Number: NAI001/I | Start Date*: 2005-11-28 |
Sponsor Name:University of Dundee ( Research & Innovation Services) | ||
Full Title: Comparative study of the bioactivity of the HFA Fluticasone Dipropionate via current delivery devices | ||
Medical condition: Bronchial Asthma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005557-22 | Sponsor Protocol Number: NAI004/I | Start Date*: 2006-02-17 |
Sponsor Name:University of Dundee (Research & Innovation) | ||
Full Title: COMPARATIVE STUDY OF THE SYSTEMIC BIOACTIVITY OF HFA FLUTICASONE PROPIONATE VIA ANTI-STATIC SPACER DEVICES | ||
Medical condition: Bronchial Asthma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-004404-21 | Sponsor Protocol Number: SLE-Omega | Start Date*: 2004-12-10 |
Sponsor Name:GreenPark Healthcare Trust [...] | ||
Full Title: Omega-3-Polyunsaturated Fatty Acids and Atherosclerosis in Systemic Lupus Erythematosus: Cellular Mechanisms and Functional Consequences | ||
Medical condition: Systemic Lupus Erythematosus | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-002084-49 | Sponsor Protocol Number: 06023GM-A | Start Date*: 2006-09-13 |
Sponsor Name:Belfast City Hospital Trust | ||
Full Title: Vascular function in impaired glucose tolerance - effect of pioglitazone | ||
Medical condition: Impaired glucose tolerance | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-020114-29 | Sponsor Protocol Number: IGFHD1-2010 | Start Date*: 2010-07-13 | |||||||||||
Sponsor Name:Department of Nephrology | |||||||||||||
Full Title: Insulin-like growth factor in hemodialysis patients | |||||||||||||
Medical condition: This project aims to investigate whether the anabolic potentials of insulin may be used to reverse the catabolic effects of hemodialysis in non-diabetic patients with end-stage renal failure. Thus... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001956-12 | Sponsor Protocol Number: NT12385-5 | Start Date*: 2011-05-25 |
Sponsor Name:University Hospital Motol | ||
Full Title: Monitoring of MxA mRNA Expression as a Marker of Rresponse to Interferon ß Therapy in Patients with Multiple Sclerosis. | ||
Medical condition: To correlate bioactivity of IFNβ reflected by level of MxA expression and clinical course of MS To measure expression of MxA protein in patients treated with IFNβ depending on NAbs status NAbs p... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001283-30 | Sponsor Protocol Number: SPK-3006-101 | Start Date*: 2020-06-16 | |||||||||||
Sponsor Name:Spark Therapeutics | |||||||||||||
Full Title: Phase 1/2, dose-escalation study to evaluate the safety, tolerability and efficacy of a single intravenous infusion of SPK-3006 in adults with late-onset Pompe disease | |||||||||||||
Medical condition: Pompe Disease (also known as glycogen storage disease type II) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) DE (Trial now transitioned) NL (Ongoing) DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003036-12 | Sponsor Protocol Number: IFX-1-P2.2 | Start Date*: 2016-04-22 | ||||||||||||||||
Sponsor Name:InflaRx GmbH | ||||||||||||||||||
Full Title: A phase II randomized, placebo-controlled, double-blind, dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamic dose response relationship of IFX-1 in patients undergoing co... | ||||||||||||||||||
Medical condition: Prevention of organ dysfunction induced by inflammatory response after complex cardiac surgery | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-000296-21 | Sponsor Protocol Number: APHP191110 | Start Date*: 2020-04-09 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Rapid rEcognition of COrticosteroid Resistant or sentive Sepsis RECORDS A Multicentre Concealed‐Allocation Multi-arms Blinded Randomized Controlled Trial to Identify the Best Sepsis Population for ... | |||||||||||||
Medical condition: Patients admitted to the ICU proven or suspected infection as the main diagnosis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002093-42 | Sponsor Protocol Number: SHP643-301 | Start Date*: 2020-02-04 | ||||||||||||||||
Sponsor Name:Shire (Shire is now part of Takeda) | ||||||||||||||||||
Full Title: SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (... | ||||||||||||||||||
Medical condition: Hereditary Angioedema (HAE) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) HU (Completed) ES (Completed) Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-001037-40 | Sponsor Protocol Number: IFX-1-P2.1 | Start Date*: 2014-02-11 | |||||||||||
Sponsor Name:InflaRx GmbH | |||||||||||||
Full Title: A phase II randomized, placebo-controlled, double-blind, dose controlled trial in patients suffering from early, newly developing abdominal or pulmonary derived septic organ dysfunction to evaluate... | |||||||||||||
Medical condition: septic organ dysfunction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
